Features that differentiate four leading COVID mAbs: Data Byte

A side-by-side look at the properties of four antiviral mAbs in development for COVID-19 illuminates variations that may yield differentiated clinical profiles.

Though all the candidates target the receptor-binding domain of SARS-CoV-2 spike, they differ in the part of the domain they target, in particular whether their epitopes overlap with the binding site for host cell receptor ACE2. The mAbs also differ in whether and how the Fc domain has been modified, and whether they are in development as monotherapy or in combinations...